Spectral launches sepsis test in Italy:
This article was originally published in Clinica
Executive Summary
Spectral Diagnostics (Toronto, Canada) has begun selling its rapid sepsis testing system in Italy, through its existing local distributor, NGC Medical (Novedrate). The EAA (endotoxin activity assay) system is used to identify patients at risk of severe sepsis. Three systems have already been placed in major Italian hospitals. Spectral Diagnostics last week announced plans for a private placement to raise Can$5m (US$4m) to back launch activities for the system.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.